Incyte Presents at EHA 2025
Pharmaceutical company Incyte has announced multiple presentations at the European Hematology Association (EHA) 2025 conference. The presentations include new late-breaking data for its mutCALR-Directed Monoclonal Antibody.
Conference Presentations
- Incyte has announced multiple presentations at the EHA 2025 conference
- New late-breaking data for mutCALR-Directed Monoclonal Antibody will be presented
Stock Price
Incyte’s stock price has fluctuated within a 52-week range of:
- Low: 53.56 USD
- High: 83.95 USD
- Current price: 68.85 USD
Technical Analysis
- Price-to-earnings ratio: 242.91
- Price-to-book ratio: 3.55